AbbVie successfully defends patents related to HUMIRA® against IPR petitions filed by Amgen
Clients AbbVie Inc.
Jones Day served as co-counsel in the successful defense of AbbVie Inc. in two IPRs brought by Amgen in connection with U.S. Patent Nos. 8,916,157 and 8,916,158 related to AbbVie's blockbuster antibody therapeutic, HUMIRA®. Following filing of the Patent Owner's Preliminary Responses by AbbVie, the PTAB denied institution of both IPRs.
Amgen Inc. v. AbbVie Biotechnology Ltd. et al., IPR2015-01514, -01517 (PTAB)